Coloplast AS (WBO:COLO)

€ 113.6 0.55 (0.49%) Market Cap: 25.41 Bil Enterprise Value: 28.34 Bil PE Ratio: 38.35 PB Ratio: 10.81 GF Score: 94/100

Q4 2024 Coloplast A/S Earnings Call Transcript
Nov 05, 2024

€119.5 (+0.38%)

Earnings
Q3 2024 Coloplast A/S Earnings Call Transcript
Aug 20, 2024

€119.65 (-4.39%)

Earnings
Q2 2024 Coloplast A/S Earnings Call Transcript
May 07, 2024

€113.4 (-3.16%)

Earnings
Q1 2024 Coloplast A/S Earnings Call Transcript
Feb 09, 2024

€120 (+10.14%)

Earnings
Q4 2023 Coloplast A/S Earnings Call Transcript
Nov 09, 2023

€96.48 (-6.69%)

Earnings
Coloplast A/S to Discuss Complete Acquisition of Kerecis Call Transcript
Sep 04, 2023
Q3 2023 Coloplast A/S Earnings Call Transcript
Aug 17, 2023

€108.85 (-1.40%)

Earnings
Coloplast A/S Announces Agreement to Acquire Kerecis Call Transcript
Jul 07, 2023
Q2 2023 Coloplast A/S Earnings Call Transcript
May 11, 2023

€125.3 (-4.39%)

Earnings
Q1 2023 Coloplast A/S Earnings Call Transcript
Feb 03, 2023

€113.55 (-1.13%)

Earnings
Coloplast A/S Annual Shareholders Meeting Transcript
Dec 01, 2022
Q4 2022 Coloplast A/S Earnings Call Transcript
Nov 07, 2022

€106.5 (-2.65%)

Earnings
Coloplast A/S Meet the Management Event Transcript
Aug 31, 2022
Q3 2022 Coloplast A/S Earnings Call Transcript
Aug 17, 2022

€119 (+5.54%)

Earnings
Q2 2022 Coloplast A/S Earnings Call Transcript
May 05, 2022

€136.5

Earnings
Coloplast A/S Virtual ESG Event Call Transcript
Mar 22, 2022
Q1 2022 Coloplast A/S Earnings Call Transcript
Jan 25, 2022

€129.35 (+2.50%)

Earnings
Coloplast A/S Annual Shareholders Meeting Transcript
Dec 02, 2021
Coloplast A/S to Acquire Atos Medical Call Transcript
Nov 08, 2021
Q4 2021 Coloplast A/S Earnings Call Transcript
Nov 01, 2021

€138.65 (-2.26%)

Earnings
Q3 2021 Coloplast A/S Earnings Call Transcript
Aug 18, 2021

€147.65 (-3.81%)

Earnings
Q2 2021 Coloplast A/S Earnings Call Transcript
May 06, 2021

€131.55 (-5.43%)

Earnings
Q1 2021 Coloplast A/S Earnings Call Transcript
Feb 02, 2021

€136.9 (+8.74%)

Earnings
Coloplast A/S at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Q4 2020 Coloplast A/S Earnings Call Transcript
Nov 03, 2020

€123.1 (-2.73%)

Earnings
Coloplast A/S Virtual Sustainability Deep-Dive Session Transcript
Oct 09, 2020
Coloplast A/S Virtual Deep-Dive Sessions Transcript
Oct 07, 2020
Coloplast A/S Virtual Capital Markets Day Transcript
Sep 29, 2020
Q3 2020 Coloplast A/S Earnings Call Transcript
Aug 18, 2020

€136 (-2.23%)

Earnings
Coloplast A/S at UBS Global Healthcare Conference (Virtual) Transcript
May 20, 2020
Q2 2020 Coloplast A/S Earnings Call Transcript
May 06, 2020

€139.65 (-3.62%)

Earnings
Coloplast A/S Revised Full Year Organic Growth and EBIT Margin Guidance for 2019/2020 Call Transcript
Mar 19, 2020
Q1 2020 Coloplast A/S Earnings Call Transcript
Feb 06, 2020

€121.4 (+3.58%)

Earnings
Coloplast A/S Annual Shareholders Meeting Transcript
Dec 05, 2019
Q4 2019 Coloplast A/S Earnings Call Transcript
Nov 05, 2019

€106.35 (-4.28%)

Earnings
Coloplast A/S Meet the Management Event Transcript
Aug 20, 2019
Q3 2019 Coloplast A/S Earnings Call Transcript
Aug 14, 2019

€107.6 (+1.41%)

Earnings
Q2 2019 Coloplast A/S Earnings Call Transcript
May 02, 2019

€93.28 (-3.04%)

Earnings

Q3 2022 Coloplast A/S Earnings Call Transcript

Aug 17, 2022 / 01:00PM GMT

Release Date Price: €119 (+5.54%)

Transcript

Operator

Welcome to the Coloplast interim financial statements for 9M 2021, '22. (Operator Instructions)

With that, I'll hand the floor to our speakers. Please begin your meeting.

Kristian Villumsen;S;President;CEO

Coloplast A

/-&

Good afternoon, and welcome to our Q3 '21/'22 Conference Call. My name Kristian Villumsen. I'm the CEO of Coloplast. And I'm joined by our CFO, Anders Lonning-Skovgaard; and our Investor Relations team. We'll start like we usually do with a short presentation by Anders and myself, and then open up for questions from you.

Please turn to Slide #3. In Q3, we delivered 8% organic growth and an EBIT margin before special items of 30%. We delivered a respectable return on invested capital of 26% after tax and before special items, impacted by the acquisition of Atos Medical. Reported growth in Danish kroner was 21%. Atos Medical contributed 9 percentage points to the reported growth and delivered double-digit underlying growth.

Before I dive into today's results, I'd

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.